Atlas Trials

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Clinical trial NCT04768426 · RECRUITING

Trial details

NCT number
NCT04768426
Sponsor
Stanford University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast CancerBreast Cancer
Start date
2021-02-03
Primary completion
2026-11-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.